Skip to main content
market.news โ€” Markets without borders
Biotech Sector

Biotech Sector News

Companies developing drugs, therapies, and diagnostics using biological processes.

What is Biotech Sector?

Biotech firms range from early-stage clinical-trial companies (binary outcomes โ€” drugs either work or don't) to large commercial-stage names (Amgen, Gilead, Vertex, Regeneron). Big Pharma (Pfizer, Merck, Novartis, Roche) increasingly acquires biotechs for pipeline. Indian biotech (Biocon) and emerging-market biosimilar makers add global dimension.

Why it matters for investors

Biotech is high-risk, high-reward โ€” successful drug approvals can create multi-bagger returns, while trial failures cause stocks to fall 50%+ overnight. The sector is rate-sensitive (long-duration cash flows) and policy-sensitive (drug pricing, FDA decisions, Medicare negotiations).

Frequently asked questions

How do I evaluate biotech stocks?

For pre-revenue: cash runway, pipeline strength, trial readouts. For commercial: revenue growth, patent cliffs, pipeline-replacement quality.

Why is biotech rate-sensitive?

Drug development has multi-year (often 10+) cash flows. Higher discount rates dramatically reduce present value, hitting biotech valuations harder than mature sectors.

๐Ÿ‡บ๐Ÿ‡ธ United States

Rhythm Pharmaceuticals Q3 Revenue Beats Estimates as Imcivree Expands US and Japan Reach

Rhythm Pharmaceuticals beat Q3 revenue estimates for Imcivree as the rare genetic obesity drug expands into US and Japan markets

Nov 4, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

BioNTech Q3 EPS Beat and AMETEK Raise 2026 Guidance: Two Sector Leaders Signal Momentum

BioNTech raised 2026 revenue guidance on Q3 EPS beat; AMETEK lifted full-year revenue and EPS estimates on acquisition momentum

Nov 4, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Travere Therapeutics Shares Plunge as Filspari Patient Ramp Disappoints, Nears 200-Day Line

Travere Therapeutics tumbled after fewer-than-expected patients started Filspari treatment, with the stock testing its critical 200-day moving average

Nov 4, 2026

๐Ÿ‡ฏ๐Ÿ‡ต Japan

Minghui Pharmaceutical and ASKA Sign Exclusive Japan License for IGF-1R Antibody MHB018A

Minghui Pharmaceutical and ASKA Pharmaceutical entered exclusive Japan license agreement for IGF-1R antibody MHB018A development and commercialization

Nov 4, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Genmab Stock Surges on Cancer Drug Breakthroughs in Clinical Pipeline

Genmab shares surged following positive clinical data for cancer drug breakthroughs

Nov 4, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Karyopharm Therapeutics Files Chapter 11 Bankruptcy on November 2, 2026

Karyopharm Therapeutics and subsidiary KPT Texas LLC filed Chapter 11 on November 2

Nov 4, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Five US Q3 Earnings Beats: Tempus AI, Axsome, Waystar, Krystal Biotech Lead Healthcare and Tech Rally

Five companies reported strong Q3 2026 earnings: Tempus AI posted 32% oncology volume growth and landed $192.5M in new pharma collaborations, while Axsome Therapeutics grew revenue 52% to $259.7M and narrowed its net loss to $12.9M

Nov 4, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

US Pharma Q3 Earnings Wave: Syndax, BioMarin, Vertex, Jazz Beat Revenue Estimates as Drug Launches Accelerate

Six US pharmaceutical companies reported Q3 2026 earnings with revenue beats across the board: Syndax posted $83.3M revenue (+82% YoY), BioMarin delivered $1,025M topping consensus, and Vertex exceeded estimates driven by its dominant cystic fibrosis franchise

Nov 4, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

Maxivision Becomes First in Telangana to Deploy VISUMAX 800 SMILE Pro Tech

Maxivision is the first corporate eye care chain in Telangana to offer SMILE Pro surgery with VISUMAX 800.

Nov 3, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Axsome Therapeutics Q3 Revenue Surges 52% but Shares Drop on Profitability Path Concerns

Axsome Therapeutics (AXSM) reported Q3 revenue surging 52% year-on-year, driven by the commercial ramp of its Auvelity (major depressive disorder) and Sunosi (narcolepsy/hypersomnia) products.

Nov 3, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

October Consensus Price Target Upgrades Average 10-20% Across Healthcare, Biotech, and Specialty Names

Eleven US-listed companies received October consensus analyst price target upgrades averaging 10-20%, with Healthcare Triangle (HCTI) standing out at a 1,900% upward revision from $3.21 to $64.26.

Nov 3, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Karyopharm Therapeutics Files Chapter 11 Amid Ayrmid Merger โ€” XPOVIO Franchise Transition Under Distress

Karyopharm Therapeutics (KPTI) filed for Chapter 11 bankruptcy protection while simultaneously pursuing a merger with Ayrmid, a company focused on developing its selinexor (XPOVIO) franchise.

Nov 3, 2026

๐Ÿ‡ธ๐Ÿ‡ฌ Singapore

iX Biopharma Says US Defence Contract for Wafermine Not at Risk Despite Nevada Partner's Licensing Gap

iX Biopharma stated its US Department of Defense supply contract for Wafermine does not depend on Nevada partner Orion Health, which lacks the required state pharmaceutical license

Nov 3, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Inovio (INO) Surges 224% on FDA Approval of Voceryq for Recurrent Respiratory Papillomatosis: First Commercial Product Validates DNA Medicine Platform

Inovio Pharmaceuticals surged 224% after FDA approved Voceryq for recurrent respiratory papillomatosis, marking the company's first commercial approval and validating its DNA medicine platform after decades of clinical development.

Nov 3, 2026

๐Ÿ‡ญ๐Ÿ‡ฐ Hong Kong

Baird Medical Signs Exclusive 19-Province China Distribution Deal with China Resources for MWA Products

Baird Medical and China Resources Pharmaceutical Commercial Group signed an exclusive distribution deal for microwave ablation products across 19 Chinese provincial markets.

Nov 2, 2026

๐Ÿ‡ญ๐Ÿ‡ฐ Hong Kong

Lynk Pharmaceuticals Extends Zemprocitinib Partnership With Simcere Into Dermatology Markets

Lynk Pharmaceuticals expanded its Simcere collaboration for Zemprocitinib into dermatology indications, broadening Greater China commercial reach

Nov 2, 2026

๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom

AnaptysBio Seen as Undervalued Versus PTCT and MIRM on Royalty Stream and Legal Upside

A special situations investor has published a bullish thesis arguing AnaptysBio is undervalued relative to biotech peers PTCT and MIRM

Nov 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Illumina Shares Crash Despite Q3 Beat as Tariff Fears and AI Tech Selloff Hit

Illumina stock crashed on Friday despite beating third-quarter earnings expectations

Nov 1, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

RPG Life Sciences Targets 25% CAGR in API Business and Plans New Acquisition

RPG Life Sciences MD Ashok Nair outlined a 25% CAGR growth target for the company's active pharmaceutical ingredient business

Nov 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Regeneron (REGN) Surges 26.3% in October on Blowout Q3 Results

Regeneron Pharmaceuticals (REGN) surged 26.3% in October driven by strong Q3 2026 earnings results.

Nov 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Acumen Pharmaceuticals Shares Plunge 80% After Alzheimer's Clinical Trial Failure

Acumen Pharmaceuticals shares collapsed 80% after its Alzheimer's disease clinical trial failed

Oct 31, 2026

Alnylam

Alnylam TTR Franchise Surges 59%, Supernus Posts Record $226.8M Revenue, BridgeBio's Attruby Up 134% in Q3 Pharma Earnings

Alnylam Pharmaceuticals' TTR franchise revenue surged 59% on strong AMVUTTRA demand, with total product revenue growing 52% in Q3 2026.

Oct 31, 2026

๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom

Exelixis Reports Q3 2026 Earnings; Oncology Biotech Posts Results as Cabozantinib Franchise Matures

Exelixis (EXEL) published its Q3 2026 earnings call slide deck, releasing results from the oncology-focused biopharmaceutical company.

Oct 30, 2026

Pharma

Incyte Q3 Net Loss on $1.23B Vega Charge; FY26 Sales Guidance Raised

Incyte Q3 net loss driven by $1.23B Vega acquisition charge, not operational decline Company raised FY26 sales guidance, citing commercial portfolio growth across hematology Q4 will be first clean quarter post-Vega; FDA pipeline and integration timelines are key

Oct 30, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Glaukos Q3 2026: 58% Revenue Growth, Return to Profit, Guidance Raised โ€” Shares Surge Pre-Market

Glaukos Corp. Q3 2026 revenue grew 58% as the ophthalmic device maker returned to profitability and raised full-year guidance

Oct 30, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

VisioSurgical Solutions Launches to Bring Compact Retinal Surgical Robots Mainstream

VisioSurgical Solutions (VSS) was launched by retinal robotics pioneers to commercialize compact surgical robots for retina procedures.

Oct 29, 2026

๐Ÿ‡ง๐Ÿ‡ท Brazil

Novartis NVS Q3 2026 Earnings Call: CEO Narasimhan Spotlights Innovative Medicine Pipeline

Novartis CEO Vasant Narasimhan led the Q3 2026 earnings call on October 27 with Kisqali and Entresto as key innovative medicine performance drivers

Oct 29, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

SoFi Technologies and Nautilus Biotechnology Both Beat Q3 Earnings Estimates

SoFi Technologies beat Q3 earnings expectations with strong revenue growth, demonstrating continued momentum in its digital banking and lending operations

Oct 28, 2026

๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom

Alnylam Pharmaceuticals RNAi Roundtable Highlights Brezosiran's Exon 1 Approach for Huntington's Disease

Alnylam Pharmaceuticals hosted an RNAi roundtable focusing on Brezosiran's exon 1 targeting strategy for Huntington's disease treatment.

Oct 27, 2026

๐ŸŒ Global

US Measles Resurgence Exposes Public Health Weaknesses, Raising Vaccine Sector Concerns

A measles resurgence in the US is exposing structural weaknesses including declining vaccination rates and waning trust in health institutions

Oct 27, 2026